Geriatric Medicine Market

Geriatric Medicines Market (Therapeutic Category - Analgesic, Antihypertensive, Statins, Antidiabetic, Proton Pump Inhibitor, Anticoagulant, Antipsychotic and Antidepressant; Condition - Cardiovascular, Arthritis, Diabetes, Neurological, Cancer, Osteoporosis, Respiratory; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

  • Rep Id : TMRGL2445
  • Published On : Nov 2018
  • No. of Pages : 185
  • Category : Pharmaceutical

Section 1 Preface 
1.1 Report Scope and Market Segmentation 
1.2 Research Highlights

Section 2 Assumptions and Research Methodology 
2.1 Assumptions
2.2 Research Methodology

Section 3 Executive Summary
3.1 Global Geriatric Medicines Market Snapshot
3.2 Global Geriatric Medicines Market Share Analysis, by Region, 2017

Section 4 Market Overview
4.1 Global Geriatric Medicines Market Taxonomy
4.2 Global Geriatric Medicines Market Value (US$ Mn) Forecast, 2016–2026
4.3 Global Geriatric Medicines Market: Market Outlook
4.4 Key Industry Events

Section 5 Market Dynamics
5.1 Drivers and Restraints Snapshot Analysis
5.2 Drivers
      5.2.1 Increase in global geriatric population
      5.2.2 Rise in chronic diseases (stroke, respiratory, and arthritis)
      5.2.3 Increase in government support for elderly
      5.2.4 Technological advancements for medication assistance
5.3 Restraints
      5.3.1 Significant shortfall of geriatricians in the world
      5.3.2 High chances of adverse drug reaction in elderly
      5.3.3 Lack of patient participation in clinical trials

Section 6 Geriatric Medicines Market Analysis, by Therapeutic Category
6.1 Key Findings
6.2 Introduction
6.3 Global Geriatric Medicines Market Value Share Analysis, by Therapeutic Category
6.4 Global Geriatric Medicines Market Forecast, by Therapeutic Category
6.5 Global Geriatric Medicines Market Analysis, by Therapeutic Category
      6.5.1 Analgesic
      6.5.2 Antihypertensive
      6.5.3 Statins
      6.5.4 Antidiabetic
      6.5.5 Proton Pump Inhibitor
      6.5.6 Anticoagulant
      6.5.7 Antipsychotic and Antidepressant 
      6.5.8 Others 

Section 7 Global Geriatric Medicines Market Analysis, by Condition
7.1 Key Findings
7.2 Introduction
7.3 Global Geriatric Medicines Market Value Share Analysis, by Condition
7.4 Global Geriatric Medicines Market Forecast, by Condition
7.5 Global Geriatric Medicines Market Analysis, by Condition 
      7.5.1 Cardiovascular
      7.5.2 Arthritis
      7.5.3 Diabetes
      7.5.4 Neurological
      7.5.5 Cancer
      7.5.6 Osteoporosis 
      7.5.7 Respiratory
      7.5.8 Others 

Section 8 Global Geriatric Medicines Market Analysis, by Distribution Channel
8.1 Key Findings
8.2 Introduction
8.3 Global Geriatric Medicines Market Value Share Analysis, by Distribution Channel
8.4 Global Geriatric Medicines Market Forecast, by Distribution Channel
8.5 Global Geriatric Medicines Market Analysis, by Distribution Channel 
      8.5.1 Hospital Pharmacies
      8.5.2 Retail Pharmacies
      8.5.3 Online Pharmacies

Section 9 Global Geriatric Medicines Market Analysis, by Region
9.1 Global Geriatric Medicines Market Value Share Analysis, by Region
9.2 Global Geriatric Medicines Market Forecast, by Region

Section 10 North America Geriatric Medicines Market Analysis, by Region
10.1 Market Overview
10.2 North America Geriatric Medicines Market Value Share and Attractiveness Analysis, by Country
10.3 North America Geriatric Medicines Market Value Share Analysis, by Therapeutic Category
10.4 North America Geriatric Medicines Market Forecast, by Therapeutic Category 
10.5 North America Geriatric Medicines Market Value Share Analysis, by Condition
10.6 North America Geriatric Medicines Market Forecast, by Condition
10.7 North America Geriatric Medicines Market Value Share Analysis, by Distribution Channel
10.8 North America Geriatric Medicines Market Forecast, by Distribution Channel
10.9 North America Geriatric Medicines Market Value Share Analysis, by Country
10.10 North America Geriatric Medicines Market Forecast, by Country
      10.10.1 U.S.
      10.10.2 Canada

Section 11 Europe Geriatric Medicines Market Analysis, by Region
11.1 Market Overview
11.2 Europe Geriatric Medicines Market Value Share and Attractiveness Analysis, by Country/Sub-region
11.3 Europe Geriatric Medicines Market Value Share Analysis, by Therapeutic Category
11.4 Europe Geriatric Medicines Market Forecast, by Therapeutic Category 
11.5 Europe Geriatric Medicines Market Value Share Analysis, by Condition
11.6 Europe Geriatric Medicines Market Forecast, by Condition
11.7 Europe Geriatric Medicines Market Value Share Analysis, by Distribution Channel
11.8 Europe Geriatric Medicines Market Forecast, by Distribution Channel
11.9 Europe Geriatric Medicines Market Value Share Analysis, by Country/Sub-region
11.10 Europe Geriatric Medicines Market Forecast, by Country/Sub-region
      11.10.1 Germany
      11.10.2 U.K.
      11.10.3 France
      11.10.4 Spain
      11.10.5 Italy
      11.10.6 Rest of Europe

Section 12 Asia Pacific Geriatric Medicines Market Analysis, by Region
12.1 Market Overview
12.2 Asia Pacific Geriatric Medicines Market Value Share and Attractiveness Analysis, by Country/Sub-region
12.3 Asia Pacific Geriatric Medicines Market Value Share Analysis, by Therapeutic Category
12.4 Asia Pacific Geriatric Medicines Market Forecast, by Therapeutic Category 
12.5 Asia Pacific Geriatric Medicines Market Value Share Analysis, by Condition
12.6 Asia Pacific Geriatric Medicines Market Forecast, by Condition
12.7 Asia Pacific Geriatric Medicines Market Value Share Analysis, by Distribution Channel
12.8 Asia Pacific Geriatric Medicines Market Forecast, by Distribution Channel
12.9 Asia Pacific Geriatric Medicines Market Value Share Analysis, by Country/Sub-region
12.10 Asia Pacific Geriatric Medicines Market Forecast, by Country/Sub-region
      12.10.1 China
      12.10.2 Japan
      12.10.3 India
      12.10.4 Australia & New Zealand
      12.10.5 Rest of APAC

Section 13 Latin America Geriatric Medicines Market Analysis, by Region
13.1 Market Overview
13.2 Latin America Geriatric Medicines Market Value Share and Attractiveness Analysis, by Country/Sub-region
13.3 Latin America Geriatric Medicines Market Value Share Analysis, by Therapeutic Category
13.4 Latin America Geriatric Medicines Market Forecast, by Therapeutic Category 
13.5 Latin America Geriatric Medicines Market Value Share Analysis, by Condition
13.6 Latin America Geriatric Medicines Market Forecast, by Condition
13.7 Latin America Geriatric Medicines Market Value Share Analysis, by Distribution Channel
13.8 Latin America Geriatric Medicines Market Forecast, by Distribution Channel
13.9 Latin America Geriatric Medicines Market Value Share Analysis, by Country/Sub-region
13.10 Latin America Geriatric Medicines Market Forecast, by Country/Sub-region
      13.10.1 Brazil
      13.10.2 Mexico
      13.10.3 Rest of LATAM

Section 14 Middle East & Africa Geriatric Medicines Market Analysis, by Region
14.1 Market Overview
14.2 Middle East & Africa Geriatric Medicines Market Value Share and Attractiveness Analysis, by Country/Sub-region
14.3 Middle East & Africa Geriatric Medicines Market Value Share Analysis, by Therapeutic Category
14.4 Middle East & Africa Geriatric Medicines Market Forecast, by Therapeutic Category 
14.5 Middle East & Africa Geriatric Medicines Market Value Share Analysis, by Condition
14.6 Middle East & Africa Geriatric Medicines Market Forecast, by Condition
14.7 Middle East & Africa Geriatric Medicines Market Value Share Analysis, by Distribution Channel
14.8 Middle East & Africa Geriatric Medicines Market Forecast, by Distribution Channel
14.9 Middle East & Africa Geriatric Medicines Market Value Share Analysis, by Country/Sub-region
14.10 Middle East & Africa Geriatric Medicines Market Forecast, by Country/Sub-region
      14.10.1 GCC
      14.10.2 South Africa
      14.10.3 Rest of MEA

Section 15 Company Profiles
            15.2.1 Pfizer, Inc.
                     15.2.1.1 Company Overview (HQ, Business Segments, Employee Strength)
                     15.2.1.2 Financial Overview
                     15.2.1.3 Product Portfolio
                     15.2.1.4 SWOT Analysis
                     15.2.1.5 Strategic Overview
            15.2.2 Merck & Co., Inc.
                     15.2.2.1 Company Overview (HQ, Business Segments, Employee Strength)
                     15.2.2.2 Financial Overview
                     15.2.2.3 Product Portfolio
                     15.2.2.4 SWOT Analysis
                     15.2.2.5 Strategic Overview
            15.2.3 AstraZeneca
                     15.2.3.1 Company Overview (HQ, Business Segments, Employee Strength)
                     15.2.3.2 Financial Overview
                     15.2.3.3 Product Portfolio
                     15.2.3.4 SWOT Analysis
                     15.2.3.5 Strategic Overview
            15.2.4 Bristol-Myers Squibb Company
                     15.2.4.1 Company Overview (HQ, Business Segments, Employee Strength)
                     15.2.4.2 Financial Overview
                     15.2.4.3 Product Portfolio
                     15.2.4.4 SWOT Analysis
                     15.2.4.5 Strategic Overview
            15.2.5 Novartis AG
                     15.2.5.1 Company Overview (HQ, Business Segments, Employee Strength)
                     15.2.5.2 Financial Overview
                     15.2.5.3 Product Portfolio
                     15.2.5.4 SWOT Analysis
                     15.2.5.5 Strategic Overview
            15.2.6 Sanofi S.A.
                     15.2.6.1 Company Overview (HQ, Business Segments, Employee Strength)
                     15.2.6.2 Financial Overview
                     15.2.6.3 Product Portfolio
                     15.2.6.4 SWOT Analysis
                     15.2.6.5 Strategic Overview
            15.2.7 GlaxoSmithKline plc
                     15.2.7.1 Company Overview (HQ, Business Segments, Employee Strength)
                     15.2.7.2 Financial Overview
                     15.2.7.3 Product Portfolio
                     15.2.7.4 SWOT Analysis
                     15.2.7.5 Strategic Overview
            15.2.8 Eli Lilly and Company
                     15.2.8.1 Company Overview (HQ, Business Segments, Employee Strength)
                     15.2.8.2 Financial Overview
                     15.2.8.3 Product Portfolio
                     15.2.8.4 SWOT Analysis
            15.2.8.5 Strategic Overview
                     15.2.9 Abbott Laboratories
                     15.2.9.1 Company Overview (HQ, Business Segments, Employee Strength)
                     15.2.9.2 Financial Overview
                     15.2.9.3 Product Portfolio
                     15.2.9.4 SWOT Analysis
                     15.2.9.5 Strategic Overview
            15.2.10 Boehringer Ingelheim GmbH
                     15.2.10.1 Company Overview (HQ, Business Segments, Employee Strength)
                     15.2.10.2 Financial Overview
                     15.2.10.3 Product Portfolio
                     15.2.10.4 SWOT Analysis
                     15.2.10.5 Strategic Overview

List of Tables

Table 01: Major Causes of Death for Persons Aged 65 or Over, 2014 (Standardized Death Rates per 100,000 Inhabitants)
Table 02: Healthcare Overview (2016 or latest available)
Table 03: Global Geriatric Medicines Market Value (US$ Mn) Forecast, by Therapeutic Category, 2016–2026
Table 04: Global Geriatric Medicines Market Value (US$ Mn) Forecast, by Condition, 2016–2026
Table 05: Global Geriatric Medicines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 06: Global Geriatric Medicines Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 07: North America Geriatric Medicines Market Value (US$ Mn) Forecast, by Therapeutic Category, 2018–2026
Table 08: North America Geriatric Medicines Market Value (US$ Mn) Forecast, by Condition, 2018–2026
Table 09: North America Geriatric Medicines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 10: North America Geriatric Medicines Market Value (US$ Mn) Forecast, by Country, 2016–2026
Table 11: Europe Geriatric Medicines Market Value (US$ Mn) Forecast, by Therapeutic Category, 2018–2026
Table 12: Europe Geriatric Medicines Market Value (US$ Mn) Forecast, by Condition, 2018–2026
Table 13: Europe Geriatric Medicines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 14: Europe Geriatric Medicines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 15: Asia Pacific Geriatric Medicines Market Value (US$ Mn) Forecast, by Therapeutic Category, 2018–2026
Table 16: Asia Pacific Geriatric Medicines Market Value (US$ Mn) Forecast, by Condition, 2018–2026
Table 17: Asia Pacific Geriatric Medicines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 18: Asia Pacific Geriatric Medicines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 19: Latin America Geriatric Medicines Market Value (US$ Mn) Forecast, by Therapeutic Category, 2018–2026
Table 20: Latin America Geriatric Medicines Market Value (US$ Mn) Forecast, by Condition, 2018–2026
Table 21: Latin America Geriatric Medicines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 22: Latin America Geriatric Medicines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 23: Middle East & Africa Geriatric Medicines Market Value (US$ Mn) Forecast, by Therapeutic Category, 2018–2026
Table 24: Middle East & Africa Geriatric Medicines Market Value (US$ Mn) Forecast, by Condition, 2018–2026
Table 25: Middle East & Africa Geriatric Medicines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 26: Middle East & Africa Geriatric Medicines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026

List of Figures

Figure 01: Global Geriatric Medicines Market Snapshot
Figure 02: Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2016–2026
Figure 03: Global Geriatric Medicines Market Value Share by Therapeutic Category (2017)
Figure 04: Global Geriatric Medicines Market Value Share by Condition (2017)
Figure 05: Global Geriatric Medicines Market Value Share by Distribution Channel (2017)
Figure 06: Global Geriatric Medicines Market Value Share by Region (2017)
Figure 07: Global Geriatric Medicines Market Value Share, by Therapeutic Category, 2017 and 2026
Figure 08: Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026, by Analgesics
Figure 09: Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026, by Antihypertensive
Figure 10: Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026, by Statins
Figure 11: Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026, by Antidiabetic
Figure 12: Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026, by Proton Pump Inhibitor
Figure 13: Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026, by Anticoagulant 
Figure 14: Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026, by Antipsychotic and Antidepressant 
Figure 15: Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026, by Others 
Figure 16: Global Geriatric Medicines Market Value Share, by Condition, 2017 and 2026
Figure 17: Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026, by Cardiovascular
Figure 18: Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026, by Arthritis
Figure 19: Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026, by Diabetes
Figure 20: Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026, by Neurological 
Figure 21: Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026, by Cancer
Figure 22: Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026, by Osteoporosis 
Figure 23: Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026, by Antipsychotic and Antidepressant 
Figure 24: Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026, by Others 
Figure 25: Global Geriatric Medicines Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 26: Global Geriatric Medicines Market Value (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2016–2026
Figure 27: Global Geriatric Medicines Market Value (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2016–2026
Figure 28: Global Geriatric Medicines Market Value (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2016–2026
Figure 29: Global Geriatric Medicines Market Value Share, by Region, 2017 and 2026
Figure 30: North America Geriatric Medicines Market Value (US$ Mn) Forecast, 2016–2026
Figure 31: North America Geriatric Medicines Market Attractiveness Analysis, by Country
Figure 32: North America Geriatric Medicines Market Value Share Analysis, by Therapeutic Category, 2017 and 2026
Figure 33: North America Geriatric Medicines Market Value Share Analysis, by Condition, 2017 and 2026
Figure 34: North America Geriatric Medicines Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 35: North America Geriatric Medicines Market Value Share Analysis, by Country, 2017 and 2026
Figure 36: Europe Geriatric Medicines Market Value (US$ Mn) Forecast, 2016–2026
Figure 37: Europe Geriatric Medicines Market Attractiveness Analysis, by Country/Sub-region
Figure 38: Europe Geriatric Medicines Market Value Share Analysis, by Therapeutic Category, 2017 and 2026
Figure 39: Europe Geriatric Medicines Market Value Share Analysis, by Condition, 2017 and 2026
Figure 40: Europe Geriatric Medicines Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 41: Europe Geriatric Medicines Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 42: Asia Pacific Geriatric Medicines Market Value (US$ Mn) Forecast, 2016–2026
Figure 43: Asia Pacific Geriatric Medicines Market Attractiveness Analysis, by Country/Sub-region
Figure 44: Asia Pacific Geriatric Medicines Market Value Share Analysis, by Therapeutic Category, 2017 and 2026
Figure 45: Asia Pacific Geriatric Medicines Market Value Share Analysis, by Condition, 2017 and 2026
Figure 46: Asia Pacific Geriatric Medicines Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 47: Asia Pacific Geriatric Medicines Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 48: Latin America Geriatric Medicines Market Value (US$ Mn) Forecast, 2016–2026
Figure 49: Latin America Geriatric Medicines Market Attractiveness Analysis, by Country/Sub-region
Figure 50: Latin America Geriatric Medicines Market Value Share Analysis, by Therapeutic Category, 2017 and 2026
Figure 51: Latin America Geriatric Medicines Market Value Share Analysis, by Condition, 2017 and 2026
Figure 52: Latin America Geriatric Medicines Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 53: Latin America Geriatric Medicines Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 54: Middle East & Africa (MEA) Geriatric Medicines Market Value (US$ Mn) Forecast, 2016–2026
Figure 55: Middle East & Africa (MEA) Geriatric Medicines Market Attractiveness Analysis, by Country/Sub-region
Figure 56: Middle East & Africa (MEA) Geriatric Medicines Market Value Share Analysis, by Therapeutic Category, 2017 and 2026
Figure 57: Middle East & Africa (MEA) Geriatric Medicines Market Value Share Analysis, by Condition, 2017 and 2026
Figure 58: Middle East & Africa (MEA) Geriatric Medicines Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 59: Middle East & Africa (MEA) Geriatric Medicines Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 60: Pfizer, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 61: Pfizer, Inc. R&D Intensity (%) - Company Level or Segment Level, 2015–2017
Figure 62: Pfizer, Inc. Breakdown of Net Sales, by Region, 2017
Figure 63: Merck & Co., Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 64: Merck & Co., Inc. R&D Intensity (%) - Company Level or Segment Level, 2014–2017
Figure 65: Merck & Co., Inc. Break-up of Net Sales, by Region, 2017
Figure 66: AstraZeneca Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 67: AstraZeneca Breakdown of Net Sales, by Region, 2017
Figure 68: AstraZeneca Marketing & Sales and R&D Expenses, 2015–2017
Figure 69: Bristol-Myers Squibb Company Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 70: Bristol-Myers Squibb Company R&D Intensity (%) - Company Level or Segment Level, 2015–2017
Figure 71: Bristol-Myers Squibb Company Breakdown of Net Sales, by Region, 2017
Figure 72: Novartis AG Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 73: Novartis AG Marketing & Sales and R&D Expenses, 2016–2017
Figure 74: Novartis AG Breakdown of Net Sales, by Business Segment, 2017
Figure 75: Novartis AG Breakdown of Net Sales, by Region, 2017
Figure 76: Sanofi S.A. Breakdown of Net Sales, by Region, 2017
Figure 77: Sanofi S.A. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 78: Sanofi S.A. Breakdown of Net Sales, by Business Segment, 2017
Figure 79: Sanofi S.A. R&D Intensity and Sales & Marketing Intensity (Pharmaceutical Segment) - Company Level, 2015–2017
Figure 80: GlaxoSmithKline plc Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 81: GlaxoSmithKline plc Marketing & Sales and R&D Expenses, 2015–2017
Figure 82: GlaxoSmithKline plc Breakdown of Net Sales, by Business Segment, 2017
Figure 83: GlaxoSmithKline plc Breakdown of Net Sales, by Region, 2017
Figure 84: Eli Lilly and Company Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 85: Eli Lilly and Company R&D Intensity (%) - Company Level or Segment Level, 2015–2017
Figure 86: Eli Lilly and Company Breakdown of Net Sales, by Region, 2017
Figure 87: Abbott Laboratories, Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 88: Abbott Laboratories, Breakdown of Net Sales, by Business Segment, 2017
Figure 89: Abbott Laboratories, Breakdown of Net Sales, by Region 2017
Figure 90: Boehringer Ingelheim GmbH, Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 91: Boehringer Ingelheim GmbH, Breakdown of Net Sales, by Business Segment, 2017
Figure 92: Boehringer Ingelheim GmbH, Breakdown of Net Sales, by Region 2017
Figure 93: Boehringer Ingelheim GmbH, R&D (US$ Mn) and Y-o-Y Growth (%), 2014–2017

.